HCW Biologics reports $3.47M profit but faces Nasdaq delisting risk in 2026

HCW Biologics has reported a net income of $3.47 million for the first quarter of 2026. The company also secured $6.54 million in revenue, mainly from a licensing deal with Beijing Trimmune. Despite these gains, financial challenges remain as the firm faces potential delisting from Nasdaq and ongoing funding concerns. The company’s financial results for Q1 2026 showed a positive turn, with net income reaching $3.47 million. Revenue hit $6.54 million, driven by a $6.5 million licensing agreement with Beijing Trimmune. However, HCW Biologics has warned of going concern uncertainty, admitting substantial doubt about its ability to continue operations for the next year without further financing.

In February 2026, the company raised $1.5 million in equity to provide short-term support. Yet, its share price has fallen below Nasdaq’s $1.00 minimum requirement, putting it at risk of delisting. A hearing on the matter is scheduled for May 5, 2026, though no decision has been announced yet. On the research front, HCW Biologics is advancing its clinical programmes. HCW9302, its lead candidate for alopecia areata, is currently in a Phase 1 study with no dose-limiting toxicities reported so far. Early-stage results from the first two dosing groups are expected in the first half of 2026. Meanwhile, HCW9206, a commercial-stage compound, could improve CAR-T cell production and boost therapeutic effects against cancer and HIV.

HCW Biologics has made progress in both financial performance and clinical development. However, its future depends on securing additional funding and resolving its Nasdaq compliance issues. The company’s next steps will determine whether it can sustain operations and advance its pipeline.